<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04146701</url>
  </required_header>
  <id_info>
    <org_study_id>2019-1093N-MA</org_study_id>
    <nct_id>NCT04146701</nct_id>
  </id_info>
  <brief_title>Metabolomics and Microbiomics in Cardiovascular Diseases Mannheim</brief_title>
  <acronym>MEMORIAM</acronym>
  <official_title>Metabolomics and Microbiomics in Cardiovascular Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsmedizin Mannheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      &quot;MEtabolomics and MicrObiomics in caRdIovAscular diseases Mannheim (MEMORIAM) &quot; is a
      single-center, prospective and observational study investigating to identify disease-specific
      metabolic, respectively microbiomic, patterns of patients with high-risk cardiovascular
      diseases. High-risk cardiovascular diseases comprise patients suffering from acute heart
      failure (AHF), ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation
      myocardial infarction (NSTEMI), sepsis, septic shock, ischemic and non-ischemic
      cardiomyopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Scientific evidence about the metabolomic and microbiomic changes in high-risk cardiovascular
      patients is still lacking.

      The acute, critical or progressive disease status predestinies to relevant changes in
      cardiovascular metobolism. High-risk patients in the present trial comprise those with acute
      heart failure, myocardial infarction (STEMI and NSTEMI), sepsis, septic shock, ischemic and
      non-ischemic cardiomyopathy with severely reduced left ventricular ejection fraction (LVEF
      &lt;35%).

      Therfore this study investigates to identify disease-specific patterns of metabolic and
      microbiomic changes. These patterns may help to understand pathophysiology at the metabolic
      stages and find out those patients being at highest risk of adverse future outcome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Disease-specific metabolic/microbiomic biomarker patterns.</measure>
    <time_frame>Within 24h after disease onset</time_frame>
    <description>Expression of disease-specific metabolic/microbiomic biomarker patterns at the time of acute disease presentation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause and cardiovascular mortality.</measure>
    <time_frame>12 months after inclusion</time_frame>
    <description>All-cause and cardiovascular mortality, at 6 months and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac rehospitalization.</measure>
    <time_frame>12 months after inclusion</time_frame>
    <description>Cardiac rehospitalization, at 6 months and 12 months.</description>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Acute Heart Failure</condition>
  <condition>NSTEMI - Non-ST Segment Elevation MI</condition>
  <condition>STEMI - ST Elevation Myocardial Infarction</condition>
  <condition>Myocardial Infarction, Acute</condition>
  <condition>Sepsis</condition>
  <condition>Cardiomyopathies</condition>
  <condition>Dilated Cardiomyopathy</condition>
  <condition>Ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Acute heart failure</arm_group_label>
    <description>All consecutive patients admitted with acute heart failure to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STEMI</arm_group_label>
    <description>All consecutive patients admitted with STEMI to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSTEMI</arm_group_label>
    <description>All consecutive patients admitted with NSTEMI to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ischemic cardiomyopathy</arm_group_label>
    <description>All consecutive patients with an implantable cardioverter defibrillator (ICD) due to ischemic cardiomyopathy and LVEF &lt;35% presenting for ICD check-up to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-ischemic cardiomyopathy</arm_group_label>
    <description>All consecutive patients with an implantable cardioverter defibrillator (ICD) due to non-ischemic cardiomyopathy and LVEF &lt;35% presenting for ICD check-up to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sepsis</arm_group_label>
    <description>All consecutive patients admitted with sepsis or septic shock to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Clinically inapparent group as controls. One venous blood withdraw will be performed. Demographic and clinical data will be documented.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>venous blood withdraw (ca. 40ml)</description>
    <arm_group_label>Acute heart failure</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Ischemic cardiomyopathy</arm_group_label>
    <arm_group_label>NSTEMI</arm_group_label>
    <arm_group_label>Non-ischemic cardiomyopathy</arm_group_label>
    <arm_group_label>STEMI</arm_group_label>
    <arm_group_label>Sepsis</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Withdrawl of peripheral venous blood (ca. 40ml) in EDTA, and ammonium heparin serum tubes at
      the time of acute disease status.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from acute cardiovascular diseases such as acute heart failure, STEMI,
        NSTEMI, ischemic and dilative cardiomyopathies and sepsis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  above mentioned diseases, diagnosis according to respective guideline

          -  written informed consent

        Exclusion Criteria:

          -  under 18 years

          -  cancer

          -  rheumatic diseases

          -  infections (except septic group)

          -  higher grade heart valve diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Behnes, PD Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University Medical Center Mannheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Behnes, PD Dr.</last_name>
    <phone>0049 621 383 6239</phone>
    <email>michael.behnes@umm.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ibrahim Akin, Prof. Dr.</last_name>
    <phone>0049 621 383 5229</phone>
    <email>ibrahim.akin@umm.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akin Ibrahim, Prof. Dr.</last_name>
      <phone>0049 621 383 5229</phone>
      <email>ibrahim.akin@umm.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsmedizin Mannheim</investigator_affiliation>
    <investigator_full_name>Michael Behnes</investigator_full_name>
    <investigator_title>PD Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

